Report Description

Global Human DNA Vaccine Market is anticipated to observe an impressive growth during the forecast period, 2024-2028 owing to growing prevalence of cancer and infectious diseases in humans. According to Global Cancer Observatory, in 2020, around 19,292,789 new cancer cases were reported worldwide. Breast Cancer, Lung Cancer, Colorectum Cancer, Prostate Cancer and Stomach Cancer were the most prevalent types of cancer cases reported in 2020. Additionally, increase in number of antibiotics resistant pathogens is further expected to drive the growth of human DNA Vaccine Market. 

The growing prevalence of different diseases has significantly increased the demand for different types of vaccines. Additionally, growing research & development activities being initiated by various governments and pharmaceutical & biotechnology companies across the globe is further expected to create lucrative opportunities for the growth of human DNA vaccine market in the coming years. In 2021, the research & development expenditure in the pharmaceutical industry across the globe was around USD238 billion.

Rise in Prevalence of Different Diseases

Globally, the cancer is the leading cause of death. According to World Health Organization, around 50,550,287 number of cancer prevalence are reported worldwide in the last five years. This is due to the physical carcinogens, such as ultraviolet and ionizing radiation, chemical carcinogens, such as asbestos, components of tobacco smoke, alcohol, aflatoxin (a food contaminant), and arsenic (a drinking water contaminant) and biological carcinogens, such as infections from certain viruses, bacteria, or parasites ae well as unhealthy lifestyle. Cancer has become a global healthcare concern. The need to develop therapies for cancer is expected to support the growth of global human DNA vaccine market. Similarly, the increasing prevalence of diseases such as HIV, Human Papillomavirus and Tuberculosis which are deadly and require a potential treatment is further expected to drive the growth of global human DNA vaccine market. As of 2021, globally around 38.4 million people were living with HIV.

 

Increase in Number of Antibiotics Resistant Pathogens

Antibiotic resistance is one of the biggest threats to global health, food security, and development. The epidemiological models describe a direct relationship between antibiotic consumption and resistant pathogen. According to World Health Organization, 32 antibiotics were identified in clinical development which addressed the top priority pathogens. Some multi and resistant bacteria called “superbugs” that cause infections are not treatable with existing antimicrobial medicines such as antibiotics. Also, certain bacteria’s have developed resistance to existing treatment options thereby creating a need to develop novel therapeutic solutions which can address the issue of antibiotic resistance. This in turn is expected to fuel the growth of Global Human DNA Vaccine Market.

 

Growth in R&D for DNA Vaccine

Rapid advancements in research and development (R&D) practices and activities are propelling the growth of the market on account of growing need of developing novel human vaccine for the treatment of different life-threatening diseases. According to Clinicaltrials.gov, 247 clinical trials are in different phases of development across the globe for Human DNA Vaccine. This clearly indicates that a lot of R&D is being done across the globe for developing human DNA vaccine for the treatment of different diseases, thereby supporting the growth of global human DNA vaccine market.

 

Recent Developments

ZyCoV-D is a DNA plasmid-based COVID-19 vaccine developed by Indian pharmaceutical company Cadila Healthcare, with support from the Biotechnology Industry Research Assistance Council in August 2021. This vaccine illustrated higher safety, efficacy, and immunogenicity. The vaccine is administered into the skin without an injection and has been found to be 67% protective against symptomatic COVID-19 in clinical trials. ZyCoV-D is a three-dose intradermal vaccine applied using The PharmaJet needle-free system, Tropis, which can significantly reduce any side effects and improved quality. Zydus Cadila has received approval for Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D.



Download Free Sample Report

 

Market Segmentation

Global Human DNA Vaccine Market can be segmented based on by mode of administration, by application, by end user, and by region. Based on mode of administration, the market can be categorized into intramuscular, subcutaneous, intradermal, and others. Based on application, the market can be fragmented into oncology, tuberculosis, HIV, human papillomavirus, and others. Based on end user, the market can be grouped into hospitals & clinics, biotechnology & pharmaceutical companies, academic & research institutions, and others.

 

Company Profiles

BOEHRINGER INGELHEIM GmbH (Merial), ELI-LILLY (Novartis Animal Health), Gene One Life Science, GEOVAX LABS, INC, Inovio Pharmaceuticals (VGX Animal Health), Genexine, Inc., VIATRIS INC. (Rottapharm Biotech), Takara Holdings (Takara Bio), ZOETIS INC. (Fort dodge Animal Health), Zydus Lifesciences Limited are some of the key players operating in the global Human DNA Vaccine market.

Attribute

Details

Base Year

2022

Historic Data

2018 – 2021

Estimated Year

2023

Forecast Period

2024 – 2028

Quantitative Units

Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

·         Mode of Administration

·         Application

·         End User

·         Region

·         Company

Regional scope

North America; Europe; Asia Pacific; South America; Middle East & Africa

Country scope

United States; Canada; Mexico; Germany; France; United Kingdom; Spain; Italy; China; India; Japan; South Korea; Australia; Brazil; Argentina; Colombia; South Africa; UAE; Saudi Arabia; South Africa; Turkey; Egypt

Key companies profiled

BOEHRINGER INGELHEIM GmbH (Merial), ELI-LILLY (Novartis Animal Health), Gene One Life Science, GEOVAX LABS, INC, Inovio Pharmaceuticals (VGX Animal Health), Genexine, Inc., VIATRIS INC. (Rottapharm Biotech), Takara Holdings (Takara Bio), ZOETIS INC. (Fort dodge Animal Health), Zydus Lifesciences Limited

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 Report Scope:

In this report, Global Human DNA Vaccine Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Human DNA Vaccine Market, By Mode of Administration:
    • Intramuscular
    • Subcutaneous
    • Intradermal
    • Others
  • Human DNA Vaccine Market, By Application:
    • Oncology
    • Tuberculosis
    • HIV
    • Human Papillomavirus
    • Others
  • Human DNA Vaccine Market, By End User:
    • Hospitals & Clinics
    • Biotechnology & Pharmaceutical Companies
    • Academic & Research Institutions
    • Others
  • Human DNA Vaccine Market, By Region:
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
    • South America
      • Brazil
      • Argentina
      • Colombia
    • Middle East & Africa
      • UAE
      • Saudi Arabia
      • South Africa
      • Turkey
      • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Human DNA Vaccine market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

It is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Clinical Trial Analysis

5.1.  Ongoing Clinical Trials

5.2.  Completed Clinical Trials

5.3.  Terminated Clinical Trials

5.4.  Breakdown of Pipeline, By Development Phase

5.5.  Breakdown of Pipeline, By Status

5.6.  Breakdown of Pipeline, By Study Application

5.7.  Breakdown of Pipeline, By Region

5.8.  Clinical Trials Heat Map

6.    Global Human DNA Vaccine Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others)

6.2.2.     By Application (Oncology, Tuberculosis, HIV, Others)

6.2.3.     By End User (Hospitals & Clinics, Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)

6.2.4.     By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)

6.2.5.     By Company (2022)

6.3.  Market Map

6.3.1.     By Route of Administration

6.3.2.     By Application

6.3.3.     By End User

6.3.4.     By Region

7.    North America Human DNA Vaccine Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Route of Administration

7.2.2.     By Application

7.2.3.     By End User

7.2.4.     By Country

7.3.  North America: Country Analysis

7.3.1.     United States Human DNA Vaccine Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Route of Administration

7.3.1.2.2.             By Application

7.3.1.2.3.             By End User

7.3.2.     Canada Human DNA Vaccine Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Route of Administration

7.3.2.2.2.             By Application

7.3.2.2.3.             By End User

7.3.3.     Mexico Human DNA Vaccine Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Route of Administration

7.3.3.2.2.             By Application

7.3.3.2.3.             By End User

8.    Europe Human DNA Vaccine Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Route of Administration

8.2.2.     By Application

8.2.3.     By End User

8.2.4.     By Country

8.3.  Europe: Country Analysis

8.3.1.     France Human DNA Vaccine Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Route of Administration

8.3.1.2.2.             By Application

8.3.1.2.3.             By End User

8.3.2.     Germany Human DNA Vaccine Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Route of Administration

8.3.2.2.2.             By Application

8.3.2.2.3.             By End User

8.3.3.United Kingdom Human DNA Vaccine Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Route of Administration

8.3.3.2.2.             By Application

8.3.3.2.3.             By End User

8.3.4.     Italy Human DNA Vaccine Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Route of Administration

8.3.4.2.2.             By Application

8.3.4.2.3.             By End User

8.3.5.     Spain Human DNA Vaccine Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Route of Administration

8.3.5.2.2.             By Application

8.3.5.2.3.             By End User

9.    Asia-Pacific Human DNA Vaccine Market Outlook

9.1.  Market Size & Forecast

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Route of Administration

9.2.2.     By Application

9.2.3.     By End User

9.2.4.     By Country

9.3.  Asia-Pacific: Country Analysis

9.3.1.     China Human DNA Vaccine Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Route of Administration

9.3.1.2.2.             By Application

9.3.1.2.3.             By End User

9.3.2.     Japan Human DNA Vaccine Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Route of Administration

9.3.2.2.2.             By Application

9.3.2.2.3.             By End User

9.3.3.     India Human DNA Vaccine Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Route of Administration

9.3.3.2.2.             By Application

9.3.3.2.3.             By End User

9.3.4.     South Korea Human DNA Vaccine Market Outlook

9.3.4.1.         Market Size & Forecast

9.3.4.1.1.             By Value

9.3.4.2.         Market Share & Forecast

9.3.4.2.1.             By Route of Administration

9.3.4.2.2.             By Application

9.3.4.2.3.             By End User

9.3.5.     Australia Human DNA Vaccine Market Outlook

9.3.5.1.         Market Size & Forecast

9.3.5.1.1.             By Value

9.3.5.2.         Market Share & Forecast

9.3.5.2.1.             By Route of Administration

9.3.5.2.2.             By Application

9.3.5.2.3.             By End User

10.  South America Human DNA Vaccine Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Route of Administration

10.2.2.  By Application

10.2.3.  By End User

10.2.4.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil Human DNA Vaccine Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Route of Administration

10.3.1.2.2.           By Application

10.3.1.2.3.           By End User

10.4.              Argentina Human DNA Vaccine Market Outlook

10.4.1.1.      Market Size & Forecast

10.4.1.1.1.           By Value

10.4.1.2.      Market Share & Forecast

10.4.1.2.1.           By Route of Administration

10.4.1.2.2.           By Application

10.4.1.2.3.           By End User

10.5.              Colombia Human DNA Vaccine Market Outlook

10.5.1.1.      Market Size & Forecast

10.5.1.1.1.           By Value

10.5.1.2.      Market Share & Forecast

10.5.1.2.1.           By Route of Administration

10.5.1.2.2.           By Application

10.5.1.2.3.           By End User

11.  Middle East and Africa Human DNA Vaccine Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Route of Administration

11.2.2.  By Application

11.2.3.  By End User

11.2.4.  By Country

11.3.              MEA: Country Analysis

11.3.1.  UAE Human DNA Vaccine Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Route of Administration

11.3.1.2.2.           By Application

11.3.1.2.3.           By End User

11.3.2.  Saudi Arabia Human DNA Vaccine Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Route of Administration

11.3.2.2.2.           By Application

11.3.2.2.3.           By End User

11.3.3.  South Africa Human DNA Vaccine Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Route of Administration

11.3.3.2.2.           By Application

11.3.3.2.3.           By End User

11.3.4.  Turkey Human DNA Vaccine Market Outlook

11.3.4.1.      Market Size & Forecast

11.3.4.1.1.           By Value

11.3.4.2.      Market Share & Forecast

11.3.4.2.1.           By Route of Administration

11.3.4.2.2.           By Application

11.3.4.2.3.           By End User

11.3.5.  Egypt Human DNA Vaccine Market Outlook

11.3.5.1.      Market Size & Forecast

11.3.5.1.1.           By Value

11.3.5.2.      Market Share & Forecast

11.3.5.2.1.           By Route of Administration

11.3.5.2.2.           By Application

11.3.5.2.3.           By End User

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

13.1.              Recent Developments

13.2.              Mergers & Acquisitions

13.3.              Product Developments

14.  Competitive Landscape

14.1.              Business Overview

14.2.              Company Snapshot

14.3.              Products & Services

14.4.              Financials (In case of listed companies)

14.5.              Recent Developments

14.6.              SWOT Analysis

14.6.1.  BOEHRINGER INGELHEIM GmbH (Merial)

14.6.2.  ELI-LILLY (Novartis Animal Health)

14.6.3.  Gene One Life Science

14.6.4.  GEOVAX LABS, INC

14.6.5.  Inovio Pharmaceuticals (VGX Animal Health)

14.6.6.  Genexine, Inc.

14.6.7.  VIATRIS INC. (Rottapharm Biotech)

14.6.8.  Takara Holdings (Takara Bio)

14.6.9.  ZOETIS INC. (Fort dodge Animal Health)

14.6.10.                Zydus Lifesciences Limited

15. Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

Global Human DNA Vaccine market is expected to grow at impressive rate on account of increasing numbers of antibiotic resistant pathogens and growing research & development for the development of novel vaccines.

down-arrow

China will be the fastest growing country in Asia pacific region due to the growing prevalence of target diseases and increasing research & development activities for the development of human DNA vaccines.

down-arrow

BOEHRINGER INGELHEIM GmbH (Merial), ELI-LILLY (Novartis Animal Health), Gene One Life Science, GEOVAX LABS, INC, Inovio Pharmaceuticals (VGX Animal Health), Genexine, Inc., VIATRIS INC. (Rottapharm Biotech), Takara Holdings (Takara Bio), ZOETIS INC. (Fort dodge Animal Health), Zydus Lifesciences Limited, among others are some of the leading players operating in the global human DNA vaccine market.

down-arrow

Rise in the stringent regulatory system for product approval and decrease in the adoption of DNA vaccines in many developing nations is expected to hinder the growth of the global human DNA vaccines market during the forecast period.

profile

Sakshi Bajaal

Business Consultant
Press Release

Global Human DNA Vaccine Market to be dominated by Oncology Application through 2028

Nov, 2022

Development of novel vaccines using recombinant DNA technology is expected to drive the growth of Global Human DNA Vaccine Market during the forecast period.